{"doi":"10.1111/jgh.12116","title":"Non‐alcoholic fatty liver disease contributes to hepatocarcinogenesis in non‐cirrhotic liver: A clinical and pathological study","abstract":"AbstractBackground and AimHepatocellular carcinoma (HCC) is a major complication of cirrhosis and has been increasing in incidence in recent years. Fatty liver disease is an increasingly common cause of chronic liver disease, and there have been several case reports of HCC in patients with non‐cirrhotic fatty liver disease. However, there is limited data from systematic studies with histological confirmation of the presence of both the HCC and the non‐cirrhotic fatty liver disease.MethodsWe studied the occurrence of fatty liver disease and the associated demographic, clinical, and pathological characteristics of a large cohort of patients with HCC in non‐cirrhotic livers. Patients with intrahepatic cholangiocarcinoma (CC) occurring in non‐cirrhotic livers and diagnosed during the same time period were used as the comparison group.ResultsSignificant steatosis in the nontumor liver had a statistically significant association with HCC, being present in 54% (85/157) of HCC compared with 27% (32/120) of CC (P < 0.0001). Steatohepatitis was present in 15% (24/157) of HCC and 1% (2/120) of CC (P = 0.0014). Furthermore, HCC was more prevalent in cases with higher grades of steatosis. In addition, the recently described intratumoral steatohepatitic morphology of HCC (SH‐HCC) was also associated with significant steatosis in nontumor liver, with significant steatosis being present in 89% with SH‐HCC compared with 50% without SH‐HCC (P = 0.0162). Finally, SH‐HCC was increasingly more prevalent in patients with higher grades of nontumor steatosis.ConclusionsTaken together, these findings suggest a strong association between fatty liver disease and HCC in non‐cirrhotic livers.","journal":"Journal of Gastroenterology and Hepatology","year":2013,"id":627156,"datarank":0.7168685239667295,"base_score":4.77912349311153,"endowment":4.77912349311153,"self_citation_contribution":0.7168685239667295,"citation_network_contribution":0.0,"self_endowment_contribution":0.7168685239667295,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":118,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":69920,"name":"Michael Torbenson","orcid":"0000-0002-8334-7725","position":1,"is_corresponding":false},{"id":452443,"name":"Tsung‐Teh Wu","orcid":null,"position":2,"is_corresponding":false},{"id":277501,"name":"Matthew M. Yeh","orcid":"0000-0002-3004-8799","position":3,"is_corresponding":false},{"id":396303,"name":"Jacob Alexander","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Non‐alcoholic fatty liver disease contributes to hepatocarcinogenesis in non‐cirrhotic liver: A clinical and pathological study","abstract":"AbstractBackground and AimHepatocellular carcinoma (HCC) is a major complication of cirrhosis and has been increasing in incidence in recent years. Fatty liver disease is an increasingly common cause of chronic liver disease, and there have been several case reports of HCC in patients with non‐cirrhotic fatty liver disease. However, there is limited data from systematic studies with histological confirmation of the presence of both the HCC and the non‐cirrhotic fatty liver disease.MethodsWe studied the occurrence of fatty liver disease and the associated demographic, clinical, and pathological characteristics of a large cohort of patients with HCC in non‐cirrhotic livers. Patients with intrahepatic cholangiocarcinoma (CC) occurring in non‐cirrhotic livers and diagnosed during the same time period were used as the comparison group.ResultsSignificant steatosis in the nontumor liver had a statistically significant association with HCC, being present in 54% (85/157) of HCC compared with 27% (32/120) of CC (P < 0.0001). Steatohepatitis was present in 15% (24/157) of HCC and 1% (2/120) of CC (P = 0.0014). Furthermore, HCC was more prevalent in cases with higher grades of steatosis. In addition, the recently described intratumoral steatohepatitic morphology of HCC (SH‐HCC) was also associated with significant steatosis in nontumor liver, with significant steatosis being present in 89% with SH‐HCC compared with 50% without SH‐HCC (P = 0.0162). Finally, SH‐HCC was increasingly more prevalent in patients with higher grades of nontumor steatosis.ConclusionsTaken together, these findings suggest a strong association between fatty liver disease and HCC in non‐cirrhotic livers.","is_dataset_classified":null,"base_score":4.77912349311153,"endowment":4.77912349311153,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23302015","pmcid":null,"openalex_id":"https://openalex.org/W1768487946","authors":[],"funders":[],"total_grants":0,"fwci":9.4912,"citation_percentile":0.98644416,"influential_citations":0,"citation_trend":[{"year":2013,"count":4},{"year":2014,"count":10},{"year":2015,"count":19},{"year":2016,"count":16},{"year":2017,"count":10},{"year":2018,"count":8},{"year":2019,"count":8},{"year":2020,"count":11},{"year":2021,"count":8},{"year":2022,"count":7},{"year":2023,"count":6},{"year":2024,"count":4},{"year":2025,"count":6},{"year":2026,"count":1}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjgh.12116","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.12116","host_type":"publisher"},{"url":"https://doi.org/10.1111/jgh.12116","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/23302015","host_type":"repository"}],"fields_of_study":["Liver Disease Diagnosis and Treatment","Hepatocellular Carcinoma Treatment and Prognosis","Liver Disease and Transplantation","Adolescent","Adult","Aged","Carcinoma, Hepatocellular","Cohort Studies","Fatty Liver","Female","Humans","Liver","Liver Neoplasms","Male","Middle Aged","Non-alcoholic Fatty Liver Disease","Prevalence","Risk","Severity of Illness Index","Young Adult"],"mesh_terms":["Adolescent","Adult","Aged","Fatty Liver","Female","Carcinoma, Hepatocellular","Humans","Liver","Liver Neoplasms","Male","Middle Aged","Risk","Severity of Illness Index","Cohort Studies","Prevalence","Young Adult","Non-alcoholic Fatty Liver Disease"],"keywords":["Medicine","Hepatocellular carcinoma","Gastroenterology","Steatosis","Fatty liver","Steatohepatitis","Cirrhosis","Internal medicine","Chronic liver disease","Liver disease","Pathology","Disease"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T16:29:02.182169Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}